HKSE - Delayed Quote HKD

Pharmaron Beijing Co., Ltd. (3759.HK)

8.820 +0.180 (+2.08%)
At close: 4:09 PM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Dr. Boliang Lou Ph.D. Chairman & CEO -- -- 1963
Mr. Xiaoqiang Lou EMBA Co-Founder, President, COO & Executive Director -- -- 1968
Mr. Shing Chung Li C.F.A., CPA CFO & Secretary of the Board -- -- 1978
Dr. Hua Yang Ph.D. Chief Scientific Officer & Deputy Manager -- -- 1962
Ms. Bei Zheng M.A, M.A. Executive VP & Executive Director -- -- 1967
Mr. Henry Tang Vice President of Legal Affairs -- -- --
Dr. Connie Sun Ph.D. Senior Vice President of Business & Corporate Development -- -- --
Ms. Celina Zhong M.B.A., MBA Senior Vice President of Human Resources -- -- --
Ms. Katherine Lee M.B.A., MBA Chief Business Officer -- -- --
Ms. Jane Zhang Ph.D. Chief Quality Officer of Discovery Services -- -- --

Pharmaron Beijing Co., Ltd.

Building 1
8th floor No. 6 Taihe Road Beijing Economic and Technological Development Zon
Beijing, 100176
China
86 10 5733 0087 https://www.pharmaron.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
20,295

Description

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, rest of Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Preparation Process Development, and Production Services; Clinical Research Services; Macromolecule and Cell, and Gene Therapy Services; and Others. The company offers laboratory chemical services, including medicinal chemistry, synthetic chemistry, analytical and purification chemistry, and computer-aided drug design; bioscience services, such as in vitro and in vivo drug metabolism and pharmacokinetics, in vitro biology and in vivo pharmacology, drug safety evaluation, and US laboratory services; and process development and production, material science/preparation, preparation development and production, and analytical development services. It also provides radiolabeling science and early clinical trial services; clinical trial and clinical research site management services; and macromolecular drug discovery and development, and production services (CDMO), as well as cell and gene therapy laboratory, and gene therapy CDMO services. In addition, the company provides safety assessment, and chemistry, manufacturing, and controls services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Corporate Governance

Pharmaron Beijing Co., Ltd.’s ISS Governance QualityScore as of April 1, 2024 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 9; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Jul 18, 2023
    Ex-Dividend Date

Upcoming Events

Related Tickers